U
42.65
1.55 (3.77%)
| Penutupan Terdahulu | 41.10 |
| Buka | 41.12 |
| Jumlah Dagangan | 356,403 |
| Purata Dagangan (3B) | 2,200,663 |
| Modal Pasaran | 2,932,370,944 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.93 |
| Harga / Jualan (P/S) | 138.38 |
| Harga / Buku (P/B) | 19.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2026 |
| Margin Operasi (TTM) | -2,815.25% |
| EPS Cair (TTM) | -4.38 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -81.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,522.46% |
| Nisbah Semasa (MRQ) | 11.99 |
| Aliran Tunai Operasi (OCF TTM) | -166.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.89 M |
| Pulangan Atas Aset (ROA TTM) | -15.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -241.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | uniQure N.V. | Bercampur | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.5 |
| Purata | 0.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.09% |
| % Dimiliki oleh Institusi | 91.95% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KAPUSTA MATTHEW C | - | 41.81 | -21,082 | -881,438 |
| Jumlah Keseluruhan Kuantiti Bersih | -21,082 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -881,438 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 41.81 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KAPUSTA MATTHEW C | Pegawai | 02 Jul 2026 | Jual automatik (-) | 21,082 | 41.81 | 881,438 |
| KAPUSTA MATTHEW C | Pegawai | 02 Jul 2026 | Pelaksanaan pilihan | 21,082 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Jun 2026 | CNBC | UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |